SAB Biotherapeutics (SABS) Other Gross PP&E Adjustments (2020 - 2026)

SAB Biotherapeutics has reported Other Gross PP&E Adjustments for 7 years, with the latest figure at $28.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 7.92% year-over-year to $28.5 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (up 7.92% YoY), and the FY2025 full-year result was $24.2 million, down 7.19% from the prior year.
• Other Gross PP&E Adjustments for Q1 2026 stood at $28.5 million, up from $24.2 million in the prior quarter.
• The five-year high for Other Gross PP&E Adjustments was $28.7 million in Q1 2024, with the low at -$1.0 million in Q2 2022.
• Historically, Other Gross PP&E Adjustments has averaged $23.6 million across 5 years, with a median of $26.2 million in 2024.
• Annual changes were most pronounced in 2023 — Other Gross PP&E Adjustments jumped 2857.96% — and 2024, when it fell 8.36%.
• SAB Biotherapeutics' Other Gross PP&E Adjustments stood at $23.8 million in 2022, then grew by 9.66% to $26.1 million in 2023, then fell by 0.0% to $26.1 million in 2024, then retreated by 7.19% to $24.2 million in 2025, then grew by 17.68% to $28.5 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at $28.5 million (Q1 2026), $24.2 million (Q4 2025), and $27.1 million (Q3 2025), per Business Quant data.